Studies have demonstrated associations between cardiovascular factors and Alzheimer disease (AD) with minimal focus on other neurodegenerative diseases. Utilizing cross-sectional data from 17,532 individuals in the National Alzheimer's Coordinating Center, Uniform Data Set, we compared the presence of cardiovascular factors [body mass index (BMI), atrial fibrillation, hypertension, hyperlipidemia, and diabetes] in individuals carrying a diagnosis of Probable AD (ProbAD), Possible AD, vascular dementia, dementia with Lewy bodies (DLB), frontotemporal dementia, Parkinson disease, progressive supranuclear palsy, or corticobasal degeneration, with that of normals. Generalized linear mixed models were fitted with age at visit, gender, and cardiovascular factors as fixed effects and Alzheimer's Disease Centers as random effects. In late life, only BMI of ProbAD and DLB patients was statistically significantly lower than that in normals (P-values <0.001). When accounting for colinearity within cardiovascular factors, a low BMI was a comorbidity of certain dementia etiologies as compared with normals. These data support a concept of disease-specific associations with certain cardiovascular factors.
I t is apparent through many epidemiological studies, including but not limited to the Honolulu Asia Aging Study, the Religious Orders Study, the 90 + study, and previous National Alzheimer's Coordinating Center (NACC) database studies, that the presence or the absence of cardiovascular factors is associated with altered risk for cognitive impairment and dementia, especially Alzheimer disease (AD) and vascular dementia (VaD). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] In midlife, these factors may increase dementia risk. However, the association between cardiovascular factors in elderly individuals, and especially in those who are already cognitively impaired, and the subsequent expression of dementia may decrease or even reverse. [9] [10] [11] [12] [13] [14] [15] This may be because the pathology underlying cognitive impairment is already well established in these individuals and could lead to certain cardiovascular comorbidity profiles.
Although the association of cardiovascular and cerebrovascular disease with VaD is appreciated easily, hypothetical molecular mechanisms have also been advanced that may explain altered associations of AD with those with cardiovascular disease or a predisposition toward it, including increased oxidative stress, deranged insulin signaling, hypercholesterolemia-induced neuronal membrane changes, and circulating inflammatory mediators. 2, 4, 16 In comparison, there has been minimal focus on whether cardiovascular factors might also have differential associations for other neurodegenerative diseases, such as dementia with Lewy bodies (DLB) and frontotemporal dementias (FTD), despite the fact that underlying DLBassociated and/or FTD-associated pathologies may be collectively responsible for up to 35% of all cases of clinical dementia. 17, 18 Furthermore, hampering an analysis of individual cardiovascular factors is the extensive colinearity among them; separating the effects of these factors from each other is necessary to truly understand specific associations with diseases.
It is critical to investigate whether specific cardiovascular factors have divergent rates of occurrence in neurodegenerative diseases in late life, as this may reflect on the pathogenesis of disease-specific etiologies and identify potential interventions. Establishing the relative timing of these processes will provide clues as to which may be risk factors and which may be disease effects. The current study utilizes cross-sectional late-life data from the NACC to determine whether associations of certain cardiovascular factors [atrial fibrillation, hypercholesterolemia, hypertension, diabetes, and body mass index (BMI)] in AD and VaD are also present in other neurodegenerative conditions including DLB, FTD, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Parkinson disease (PD), or prion disease (Prion) as compared with a group of elderly individuals with no evidence of cognitive impairment, dementia, or parkinsonism (normals). The overarching hypothesis of the current study is that cardiovascular factors associated with AD in late life will not be associated with other neurodegenerative diseases. This hypothesis is in support of the contention that it is through specific mechanisms that certain cardiovascular factors are a comorbidity of AD, and there is no global association of cardiovascular factors with all neurodegenerative diseases.
METHODS

Clinical Subject Selection
The Uniform Data Set (UDS) is composed of standardized clinical evaluations collected at all Alzheimer's Disease Centers (ADCs) funded by the National Institute on Aging. The UDS includes information on demographics, behavioral symptoms, cognitive testing, medical history, family history, clinical impressions, and diagnoses. 19, 20 The present analysis includes data from 34 federally funded ADCs. Participant data were collected under Institutional Review Board approval from the 34 ADCs; the current study was approved by the Institutional Review Board at the Banner Sun Health Research Institute. Detailed description and documentation of the UDS and the NACC database can be found at the following URL: http://www.alz.washington.edu/. We utilized data from the NACC UDS (September 2014 data freeze) that consisted of demographic and clinical data on 30,953 participants from their last recorded visits. Figure 1 provides a flow chart of inclusion/exclusion criteria. Individuals were excluded if they had diagnoses other than the ones of interest at their last visit: alcohol dementia, dementia undefined, mild cognitive impairment, Huntington disease, cognitive dysfunction due to illness, hydrocephalus, brain injury, Down syndrome, cognitive dysfunction from medical illnesses, cognitive dysfunction from medications, brain cancer, and other major psychiatric illnesses. To better evaluate disease-specific mechanisms, individuals were included only if they had a single clinical diagnosis of one the following: normal cognition, CBD, DLB, FTD, PD, AD, Prion, PSP, and VaD. For example, patients with AD and contributing VaD were excluded (ie, mixed dementia or mixed neurodegenerative diagnoses). Furthermore, because of the relatively rare nature of FTD subtypes, and thus smaller sample sizes, the FTD group was collapsed and comprised of patients with any one of the following primary diagnoses: primary progressive aphasia, progressive nonfluent aphasia, all forms of semantic dementia, and the behavioral variant of FTD. Lastly, due to the focus on late-life manifestations of cardiovascular factors in persons with a neurological diagnosis, we excluded individuals who had diabetes, atrial fibrillation, hypertension, and hyperlipidemia that were listed as remote/inactive on their UDS form as the age at onset for these conditions were not recorded.
Using these inclusion and exclusion criteria, 17,532 individuals were included and assigned to one of the following clinical diagnostic categories on the basis of their last visit: probable AD (ProbAD; n = 6555), possible AD (PossAD; n = 683), VaD (n = 140), DLB (n = 339), FTD (n = 778), PD (n = 310), PSP (n = 63), CBD (n = 80), or Prion (n = 71). Individuals who had normal cognition at all visits (NACCNORM variable within the NACC UDSderived variables) and who lacked a diagnosis of PSP, CBD, and PD were considered to be normal (normals, n = 8513) and served as the reference group.
Cardiovascular Factor Data
Cross-sectional data on cardiovascular factors were obtained from the last recorded visit in the NACC database. Cardiovascular data included the BMI (the weight in kg divided by the height in meters squared), hypertension, diabetes, hyperlipidemia, and atrial fibrillation. Individuals with cardiovascular factors listed as recent/active were compared with the absent category. To provide more meaningful clinical applications, individuals were also divided into 4 categories on the basis of their BMI: underweight (BMI < 18.5), normal BMI (18.5 < BMI < 25), overweight (25 < BMI < 30), and obese (BMI > 30). Data on the age at visit, the sex, the APOE E4 carrier status, and the smoking history (at least 100 lifetime cigarettes) were also noted.
Statistical Analysis
All analyses were conducted using the SAS statistical software (Version 9.2; SAS Institute Inc., Cary, NC) and Systat (Systat Inc., San Jose, CA). Categorical variables were assessed using w 2 tests for proportional differences. Continuous variables were analyzed using a 1-way ANOVA. To address colinearity within cardiovascular factors and understand relationships of cardiovascular factors (atrial fibrillation, hypercholesterolemia, hypertension, diabetes, and BMI) with certain neurodegenerative diseases (CBD, DLB, FTD, PD, ProbAD, PossAD, PSP, and VaD) and Prion as compared with normals, we fitted generalized linear mixed models (using PROC GLIMMIX in SAS). These models are fitted under the assumption that the outcome is influenced by both fixed and random effects. Fixed effects included the sex, the age at the last visit, and all cardiovascular factors (atrial fibrillation, hypercholesterolemia, hypertension, diabetes, and BMI) analyzed. 21 Although ADCs share common components and features, each ADC has unique research questions and methods 20 leading to clustered data; hence, individual ADCs were considered as a random effect in the GLIM-MIX model. Given that approximately 40% of the APOE values were unavailable in our series, the APOE genotype was not included in the models. Each disease (CBD, DLB, FTD, PD, ProbAD, PossAD, PSP, Prion, and VaD) was run separately as an outcome variable with normal cognition as the reference group. A False Discovery Rate 22 was used to correct for multiple comparisons setting an a-level of 0.001.
RESULTS
Clinical Data and Demographics
Demographics for each group are listed in Table 1 . Frequencies of cardiovascular factors and average BMIs for each group are listed in Table 2 . Supplemental Figure 1 (Supplemental Digital Content 1, http://links.lww.com/ WAD/A133) displays the relative frequency of the disease groups and normals in the series, normal and ProbAD being the most common diagnoses (49% and 37%, respectively).
The Presence of Cardiovascular Factors Across Clinical Groups
Summaries of results from generalized linear mixed models comparing each disease group with normals adjusted for age at visit, gender, and cardiovascular factors are listed in Table 3 . In the current series, individuals with a diagnosis of ProbAD were more likely to have recent/active atrial fibrillation at the time of their last visit as compared with normals (P < 0.0001). Furthermore, individuals with a diagnosis of DLB and ProbAD were more likely to have lower BMI than normals (P-values <0.0001). As expected, given the diagnostic criteria for VaD, 2 persons who had recent/active hypertension at the time of their last visit were more likely to have a diagnosis of VaD than normals (P < 0.001). There were no other statistically significant associations meeting the prescribed a-level. Furthermore, there were several statistically significant associations between demographic variables such as the sex and the age at visit with each cardiovascular factor; odds ratios and 95% confidence intervals and the corresponding P-values are listed in Supplemental Figure 2 demonstrates the frequencies of individuals in each disease category who fell within ranges for underweight, normal BMI, overweight, or were obese at the time of their last visit. Given a set a-level of 0.001 compared with normals, those with ProbAD were more likely to be underweight (3% vs. 1%, P < 0.001). Individuals with ProbAD were more likely to be within the normal BMI range compared with normals (40% vs. 36%, P < 0.001). Individuals with ProbAD and DLB were significantly less likely to be obese when compared with normals (20%, 15%, and 26%, respectively; P values <0.001 for both comparisons). There were no differences across any groups in the overweight category (overall P-value = 0.27).
BMI by Category
DISCUSSION
This study used cross-sectional clinical data from the NACC UDS to investigate several neurodegenerative diseases and their association with the presence or the absence of late-life cardiovascular factors as compared with normals. Our findings support a hypothesis that associations between late-life cardiovascular factors and neurodegenerative disease may be restricted to AD and VaD, and possibly DLB. The findings also support the emerging understanding, demonstrated convincingly by several independent groups, that in late life, once an individual has dementia, cardiovascular factors are often less prevalent. 3, 5, 7, 10, 12, 23, 24 This is critical because certain factors, such as BMI, may be a disease-specific comorbidity.
Much evidence for the relationships of cardiovascular factors with neurodegenerative diseases have been derived from studies of AD, or from studies in which AD was most likely the dominant cause of dementia or cognitive impairment (for review, see Emmerzaal et al 9 ). This is one of the first studies to investigate how late-life non-AD neurodegenerative diseases might be associated with certain cardiovascular factors. These results demonstrate a specific association of AD and DLB with cardiovascular factors, especially with respect to the BMI. As autopsy studies have shown that Z80% of the individuals with DLB also meet the neuropathologic criteria for AD, 25 hence, it is quite possible that the DLB association may be due to underlying AD. Given that the individuals already presented with the specific neurodegenerative disease (AD, DLB), these data suggest that a lower BMI may be a comorbidity of certain dementia subtypes.
For a disease-specific molecular explanation, one may look at hypothalamic neurofibrillary tangles that are known to occur very early in the AD process. 26, 27 The hypothalamus has been known to exert central control over peripheral glucose, fat, and energy metabolism. 28 Neurofibrillary pathologies may cause disruptions in appetite, or perhaps, given that AD has been associated with lower levels of brain glucose uptake and metabolic dysfunction, 29 stores within the periphery may be depleted to compensate for brain metabolic demand, leading to a lower BMI. More detailed research is needed to confirm this hypothesis. Other hypotheses to account for the association of a lower BMI once AD is present may revolve around nonspecific effects of neurodegenerative diseases, such as the mental stress of life, nihilistic apathy that may exist once a patient has a terminal disease such as dementia, a decrease in activities of daily living (ie, grocery shopping, cooking), and a loss of recall and understanding due to cognitive dysfunction, which may lead to undernutrition. 13, [30] [31] [32] The current study revealed that BMI was not associated with PD, Prion, FTD, PSP, or CBD even after adjusting for confounders such as age. Another hypothesis concerns the hyposmia often observed in prodromal stages of AD; however, early hyposmia is also present in other diseases such as PD, [33] [34] [35] [36] which did not show any significant association with the BMI. The absence of significant relationships between cardiovascular factors and other dementias may support the fact that certain neuropathologic features may be sufficient for the development of dementia. In contrast, significant relationships between certain cardiovascular factors and AD suggest that cerebrovascular disease could potentially contribute to the development of dementia. 37 Cardiovascular damage has been reported to be common within the setting of neuropathologically confirmed AD. 4, 38, 39 Some studies have even suggested that cardiovascular damage is associated with accelerated cognitive decline within the setting of AD. 38, 40 Furthermore, a study conducted by our colleagues suggests that AD is more closely related to cerebrovascular disease rather than coronary artery disease. 12 Another possibility for the discrepant associations between cardiovascular factors, AD, and non-AD dementias may be related to group differences in the severity and the duration of dementia, as both a more severe cognitive deficit and a longer disease duration are likely to result in more weight loss and greater reversal or loss of cardiovascular factors. Further analysis investigating the relationship of BMI with dementia severity and progression is warranted. There are numerous strengths to utilizing NACC data to answer questions such as the ones posed in this study. Standardized data collection protocols used across ADCs as well as the large number of individuals in each disease group provide reliable estimates of cardiovascular factors for those in each disease group and allow for statistical models such as the ones presented here. Identification of the associations of cardiovascular factors among different neurodegenerative diseases may have important implications, including the possibility of an AD-specific molecular mechanism and the possibility of prevention or slowing of disease progression through lifestyle modifications and medications. There are some limitations that should be mentioned with respect to this study. Because many of the ADCs focus on elderly individuals, the current study was unable to analyze these factors earlier in life. In addition, persons who die in middle age or younger old age, for example, due to more severe vascular disease, would generally not have been included in this study. Furthermore, although we wished to analyze autopsy-confirmed diagnoses, neuropathology data were available for a minimal percentage of the reported series (< 10%), and these small numbers caused quasi-separation during the modeling process and resulted in either inconsistent results or nonconvergence; hence, we used the much larger clinical dataset.
Despite these limitations, these results support a concept of a disease-specific late-life association with BMI. Given the cross-sectional nature of our study, we cannot readily determine causality. Although the current study provides evidence of a lower BMI being a comorbidity of certain dementias, future longitudinal studies spanning from midlife to death, investigating the concordance of clinical and neuropathologic diagnoses in the context of cardiovascular conditions, accounting for colinearity are warranted.
